Vonoprazan

Vonoprazan is an active pharmaceutical ingredient (API) used in the treatment of acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Helicobacter pylori infection. It belongs to the class of potassium-competitive acid blockers (P-CABs) and works by reversibly inhibiting the gastric H⁺/K⁺-ATPase enzyme, resulting in rapid, potent, and sustained suppression of gastric acid secretion.

Vonoprazan is manufactured under stringent quality and regulatory standards to ensure high purity, consistent potency, and reliable performance. It is suitable for formulation development, clinical research, and commercial pharmaceutical manufacturing, supporting the production of advanced acid-suppressive therapies.